Previous 10 | Next 10 |
MacroGenics, Inc. (MGNX) Q1 2020 Earnings Conference Call May 5, 2020 04:30 PM ET Company Participants Anna Krassowska - VP, IR and Corporate Communications Scott Koenig - President and CEO Jim Karrels - SVP, CFO and Secretary Conference Call Participants Christopher Marai ...
MacroGenics (NASDAQ: MGNX ): Q1 GAAP EPS of -$0.91 beats by $0.11 . More news on: MacroGenics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
ROCKVILLE, Md., May 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progre...
Rockville, MD, April 29, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced three clinical presentations...
Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that its 2020 Annual Meeting...
Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will releas...
Rockville, MD, April 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced data related to flotetuzumab...
Bull markets are born on pessimism, grown on skepticism, mature on optimism and die on euphoria. - Sir John Templeton One of the best times for you to invest in a stock is when it tumbled far below its true worth. This usually occurs during a downturn like this Corona bear market. Howeve...
Image source: The Motley Fool. Macrogenics Inc (NASDAQ: MGNX) Q4 2019 Earnings Call Feb 25, 2020 , 4:30 p.m. ET Operator Continue reading
Start Time: 16:30 End Time: 17:23 MacroGenics, Inc. (MGNX) Q4 2019 Earnings Conference Call February 25, 2020, 16:30 PM ET Company Participants Scott Koenig - President and CEO Jim Karrels - SVP, CFO and Secretary Anna Krassowska - VP, IR and Corporate Communications Confe...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.07% on the day to $4.7. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved pr...
SAN FRANCISCO, July 03, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...